N,N'-(Hexane-1,6-diyl)bis(3-(3,5-di-tert-butyl-4-hydroxyphenyl)propanamide), 97%, 500g

N-(2-Methoxybenzyl)piperidine-4-amine dihydrochloride, 95.0%, 100mg

6-(Trifluoromethoxy)quinoline-3-carboxylic acid, 95%, 250mg

N-Fmoc-glycyl-L-valine, 98.0%, 5g

tert-Butyl 3-oxo-2,8-diazaspiro[4.5]decane-8-carboxylate, 95.0%, 250mg

4-CHLORO-5-IODO-7-ISOPROPYL-7H-PYRROLO[2,3-D]PYRIMIDINE, 95.0%, 1g

5-BROMO-1-(2,4-DIMETHOXYBENZYL)TETRAZOLE, 97.0%, 250mg

(R)-3-tert-Butoxycarbonylamino-4-phenyl-butyric acid, 95.0%, 250mg

Plan phase S40x/0.65 infinity corrected objective

(S)-1-((5-chloropyridin-3-yl)methyl)-8-((R)-3-methylmorpholino)-2-(trifluoromethyl)-3,4-dihydro-1H-pyrimido[1,2-a]pyrimidin-6(2H)-one, 1mg

Ammonia solution 15%, extra pure, 10 l, plastic packaging.

4-Methylumbelliferyl 2-Acetamido-2-deoxy-beta-D-galactopyranoside>98.0%(HPLC)1g

(2-Chloropyridin-4-yl)methanamine hydrochloride, 95.0%, 5g